Last 46 quarters of trend data · Healthcare · Drug Manufacturers - Specialty & Generic
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Collegium Pharmaceutical, Inc.'s quarterly P/E stands at 20.7x, down 79.6% year-over-year — suggesting improving earnings relative to price. EV/EBITDA has expanded 164.1% YoY to 14.6x, reflecting rising market expectations or slowing EBITDA growth.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 21.85 | 20.67 | 25.16 | 10.41 | 21.74 | 101.39 | 20.46 | 35.78 | 15.48 | 13.67 | 9.38 | 10.54 | 15.80 |
| — | -79.6% | +23.0% | -70.9% | +40.4% | +641.8% | +118.1% | +239.4% | -2.0% | — | — | -96.5% | — | |
| P/S Ratio | 1.57 | 1.71 | 2.24 | 1.65 | 1.54 | 1.38 | 1.58 | 2.44 | 2.24 | 2.77 | 2.12 | 1.72 | 1.70 |
| — | +24.2% | +41.7% | -32.3% | -31.3% | -50.3% | -25.6% | +41.7% | +31.8% | +95.2% | +41.2% | +57.7% | +39.3% | |
| P/B Ratio | 4.97 | 4.24 | 6.09 | 5.02 | 4.98 | 4.18 | 5.02 | 6.62 | 6.00 | 7.24 | 6.50 | 5.26 | 4.59 |
| — | +1.4% | +21.3% | -24.2% | -17.1% | -42.2% | -22.8% | +26.1% | +30.9% | +58.1% | +62.6% | +87.1% | +50.4% | |
| P/FCF | 3.74 | 5.83 | 3.76 | 4.41 | 3.99 | 4.49 | 3.42 | — | 4.84 | 6.55 | 4.34 | 3.18 | 2.31 |
| — | +29.8% | +9.9% | — | -17.6% | -31.5% | -21.3% | — | +109.7% | -12.5% | +45.7% | -2.1% | -38.7% | |
| EV / EBITDA | 4.63 | 14.58 | 2.76 | 4.47 | 5.09 | 5.52 | 5.12 | 7.79 | 5.08 | 5.92 | 4.39 | 4.26 | 4.74 |
| — | +164.1% | -46.1% | -42.7% | +0.1% | -6.7% | +16.6% | +82.9% | +7.4% | +9.3% | -26.7% | -13.5% | -24.0% | |
| EV / EBIT | 10.23 | 14.58 | 4.72 | 8.23 | 12.45 | 18.07 | 12.14 | 17.57 | 9.44 | 9.31 | 6.46 | 7.06 | 8.82 |
| — | -19.3% | -61.1% | -53.2% | +31.9% | +94.0% | +87.8% | +148.7% | +7.0% | -89.4% | -74.9% | -49.8% | -68.2% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Collegium Pharmaceutical, Inc.'s operating margin was 16.5% in Q1 2026, down 12.3 pp QoQ and up 4.3 pp YoY. This marks the 3rd consecutive quarter of margin compression, signaling a persistent pressure on profitability that investors should monitor. The trailing four-quarter average of 23.6% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin expanded 10.7% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 59.3% | 60.6% | 62.5% | 61.7% | 57.7% | 54.8% | 54.0% | 60.8% | 62.5% | 63.1% | 63.2% | 58.7% | 54.5% |
| — | +10.7% | +15.7% | +1.5% | -7.8% | -13.2% | -14.5% | +3.4% | +14.8% | +18.0% | +64.5% | +26.8% | +28.5% | |
| Operating Margin | 24.0% | 16.5% | 28.8% | 30.4% | 18.7% | 12.2% | 20.9% | 21.9% | 32.7% | 34.1% | 41.2% | 32.9% | 26.3% |
| — | +35.4% | +37.6% | +38.9% | -42.9% | -64.3% | -49.2% | -33.6% | +24.3% | +100.7% | +354.2% | +104.3% | +192.3% | |
| Net Margin | 8.1% | 7.5% | 8.3% | 15.0% | 6.4% | 1.4% | 6.9% | 5.9% | 13.5% | 19.1% | 21.3% | 15.1% | 9.6% |
| — | +450.9% | +19.8% | +156.8% | -52.8% | -92.9% | -67.7% | -61.2% | +40.6% | +258.9% | +484.0% | +4094.9% | +328.4% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 23.7% | 4.7% | 5.9% | 12.4% | 5.1% | 1.0% | 5.4% | 4.1% | 8.9% | 13.3% | 17.1% | 10.9% | 6.8% |
| — | +352.5% | +8.7% | +200.1% | -42.5% | -92.1% | -68.3% | -61.9% | +30.7% | +242.6% | +564.7% | +4595.1% | +359.2% | |
| ROA | 3.8% | 0.9% | 1.0% | 2.0% | 0.7% | 0.1% | 0.8% | 0.7% | 1.8% | 2.5% | 2.8% | 1.7% | 1.1% |
| — | +497.3% | +36.7% | +183.6% | -58.9% | -94.0% | -72.4% | -59.8% | +68.9% | +268.2% | +554.0% | +4513.9% | +357.1% | |
| ROIC | 14.0% | 2.6% | 4.4% | 4.8% | 2.7% | 1.6% | 2.7% | 3.1% | 5.8% | 5.9% | 7.3% | 5.1% | 3.8% |
| — | +60.0% | +59.6% | +53.9% | -52.9% | -72.5% | -62.4% | -39.0% | +51.6% | +131.7% | +530.5% | +171.1% | +289.9% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Collegium Pharmaceutical, Inc.'s Debt/EBITDA ratio is 25.3x, up from 4.1x last quarter — elevated, raising questions about debt serviceability. The current ratio has improved 58.2% YoY to 1.71x, strengthening the short-term liquidity position. Debt/Equity has declined for 6 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 3.12 | 2.59 | 3.12 | 3.41 | 3.57 | 3.60 | 3.75 | 3.73 | 2.58 | 2.84 | 3.45 | 4.02 | 3.80 |
| — | -28.2% | -17.0% | -8.7% | +38.2% | +27.0% | +8.8% | -7.1% | -32.0% | -36.8% | -5.2% | +8.2% | -0.6% | |
| Debt / EBITDA | 2.28 | 25.28 | 4.11 | 7.79 | 9.04 | 10.79 | 9.08 | 11.42 | 6.75 | 7.42 | 6.94 | 8.75 | 10.32 |
| — | +134.3% | -54.8% | -31.7% | +34.0% | +45.4% | +30.8% | +30.5% | -34.6% | -42.2% | -46.3% | -30.2% | -32.3% | |
| Current Ratio | 1.57 | 1.71 | 1.57 | 1.36 | 1.18 | 1.08 | 0.95 | 0.97 | 1.11 | 1.21 | 1.17 | 1.16 | 1.24 |
| — | +58.2% | +66.0% | +40.3% | +7.0% | -10.3% | -19.4% | -16.4% | -10.5% | +0.0% | +21.2% | +18.2% | +25.1% | |
| Quick Ratio | 1.48 | 1.62 | 1.48 | 1.27 | 1.10 | 1.01 | 0.88 | 0.88 | 1.04 | 1.14 | 1.10 | 1.08 | 1.18 |
| — | +60.4% | +68.6% | +43.9% | +5.3% | -11.5% | -20.5% | -18.4% | -11.1% | +0.9% | +28.1% | +31.8% | +46.9% | |
| Interest Coverage | 2.13 | 2.02 | 1.28 | 3.00 | 1.83 | 1.15 | 1.76 | 1.85 | 2.87 | 3.11 | 3.42 | 2.39 | 1.81 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 46 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Start ComparisonQuick answers to the most common questions about buying COLL stock.
Collegium Pharmaceutical, Inc.'s current P/E is 21.8x. The average P/E over the last 4 quarters is 19.5x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Collegium Pharmaceutical, Inc.'s current operating margin is 24.0%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Collegium Pharmaceutical, Inc.'s business trajectory between earnings reports.